100 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27914947	11	Synthesis and binding monitoring of a new nanomolar PAMAM-based matrix metalloproteinases inhibitor (MMPIs).	University Of Florence
27825552	152	Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.	Takeda Pharmaceutical
26653735	81	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Pfizer
26753813	22	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.	University Of Minnesota
25264600	64	Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.	Takeda Pharmaceutical
25265401	38	Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.	Universidad Ceu San Pablo
25192810	66	Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.	Takeda Pharmaceutical
24044937	59	Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.	University Of Lille
24900710	25	Discovery of a New Class of Potent MMP Inhibitors by Structure-Based Optimization of the Arylsulfonamide Scaffold.	University Of Florence
23631440	44	Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.	Florida State University
23437776	37	Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.	Mayo Clinic
17275314	701	Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.	Pomona College
21780776	40	Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.	Wroclaw University Of Technology
22737278	44	Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.	TBA
22175799	22	Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.	Alantos Pharmaceuticals
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University Of Florida
18053726	364	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.	Johnson & Johnson Pharmaceutical Research & Development
18251495	69	Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
18061445	103	Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).	Bristol-Myers Squibb Research And Development
17127067	21	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.	Instituto Superior T£Cnico
15713379	40	N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.	Universit£
12773042	195	Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
11472217	157	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.	Dupont Pharmaceuticals
11472202	143	Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.	TBA
10669559	180	Protease inhibitors: current status and future prospects.	University Of Queensland
10649971	180	Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.	Parke-Davis Pharmaceutical Research
10882358	62	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.	F. Hoffmann-La Roche
10579818	162	Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.	Procter And Gamble Pharmaceuticals
9888835	42	Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.	Procter And Gamble Pharmaceuticals
9733482	31	Discovery of potent, achiral matrix metalloproteinase inhibitors.	Procter And Gamble Pharmaceuticals
11327577	86	Heterocycle-based MMP inhibitors with P2' substituents.	Procter And Gamble Pharmaceuticals
22175825	19	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Pfizer
22017539	75	Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.	Boehringer Ingelheim Pharmaceuticals
22017477	35	Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.	Instituto Superior T£Cnico
22153340	37	Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).	Pfizer
21866961	28	Selective water-soluble gelatinase inhibitor prodrugs.	University Of Notre Dame
20726512	282	Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.	Pfizer
20638281	56	Structure and activity relationships of tartrate-based TACE inhibitors.	Merck Research Laboratories
21507637	102	MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.	Pfizer
21458257	87	2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.	Merck Research Laboratories
24900296	38	Sulfonate-Containing Thiiranes as Selective Gelatinase Inhibitors	TBA
20965620	50	Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs).	Protera
21106451	39	Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.	Merck Research Laboratories
20529684	112	Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.	Pfizer
20172725	49	Discovery and SAR of hydantoin TACE inhibitors.	Merck Research Laboratories
20022498	71	The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.	Schering-Plough Research Institute
20005097	58	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
19703773	63	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.	Gsk Medicines Research Centre
19524436	27	Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group.	University Of Shizuoka And Global Coe Program
19725580	93	Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.	Wyeth Research
18835710	69	Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.	Schering-Plough Research Institute
	97	Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocket	TBA
	36	Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2′-P3′ amide bond isostere	TBA
	40	Novel indolactam-based inhibitors of matrix metalloproteinases	TBA
18790648	317	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.	University Of Athens
18782669	90	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.	Université
18442906	40	Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.	North Dakota State University
17719700	39	Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.	Università
17623656	34	Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.	Pfizer
17576061	132	Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17368021	55	Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
17276676	112	A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17088065	106	alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.	Università
17027261	153	Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
16516466	175	Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16473009	23	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16392792	29	Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.	Aventis Pharma Deutschland
16153831	87	Synthesis and SAR of highly selective MMP-13 inhibitors.	Wyeth Research
16005220	52	Identification of potent and selective MMP-13 inhibitors.	Wyeth Research
14711305	26	Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.	University Of Athens
14684295	109	Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.	Chinese Academy Of Sciences
12877590	28	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.	Pfizer
12798337	6	Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.	Indiana University School Of Medicine
12408705	73	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.	Bristol-Myers Squibb
11754593	148	Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.	Abbott Laboratories
11585440	76	Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.	Dupont Pharmaceuticals
11551755	18	Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.	British Biotech Pharmaceuticals
11454461	111	The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.	Procter And Gamble Pharmaceuticals
11412980	48	Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.	Abbott Laboratories
11327602	58	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.	Roche Research Center
11150165	228	Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.	Procter And Gamble Pharmaceuticals
10669564	189	Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.	Procter And Gamble Pharmaceuticals
10639284	119	Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.	University Of Florida
10411481	144	Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.	Cea
9873712	109	Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.	Abbott Laboratories
9873491	56	The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.	Abbott Laboratories
9632351	36	Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.	Affymax Research Institute
9484512	130	Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.	Shionogi
21524149	13	Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.	Suven Life Sciences
8632342	110	Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences.	Eli Lilly
7651361	32	Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.	Georgetown University
7518496	9	Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase.	Syntex Discovery Research
7515823	54	Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family.	Novo Nordisk
7509389	8	Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.	Fujisawa Pharmaceutical